TY - JOUR
T1 - Carbon Ion Radiation Therapy for Unresectable Sacral Chordoma
T2 - An Analysis of 188 Cases
AU - Imai, Reiko
AU - Kamada, Tadashi
AU - Araki, Nobuhito
AU - Abe, Satoshi
AU - Iwamoto, Yukihide
AU - Ozaki, Toshifumi
AU - Kanehira, Chihiro
AU - Kaya, Mitsunori
AU - Takahashi, Kazuhisa
AU - Chuman, Hirokazu
AU - Tsujii, Hirohiko
AU - Tsuneyoshi, Masazumi
AU - Nishida, Yoshihiro
AU - Hiraga, Hiroaki
AU - Hiruma, Toru
AU - Machinami, Rikuo
AU - Matsumine, Akihiko
AU - Matsumoto, Seiichi
AU - Morioka, Hideo
AU - Yamaguchi, Takehiko
AU - Yonemoto, Tsukasa
N1 - Publisher Copyright:
© 2016 Elsevier Inc.
PY - 2016/5/1
Y1 - 2016/5/1
N2 - Purpose To evaluate the results of carbon ion radiation therapy administered to 188 patients with unresectable primary sacral chordomas. Patients and Methods One hundred eighty-eight patients were treated with carbon ion radiation therapy at a single institute between 1996 and 2013 and retrospectively analyzed. The median age was 66 years. The highest proximal invasion reached past S2 level in 137 patients. The median clinical target volume was 345 cm3. One hundred six patients received 67.2 gray equivalents (GyE)/16 fractions (fr), 74 patients received 70.4 GyE/16 fr, 7 patients received 73.6 GyE/16 fr, and 1 patient received 64.0 GyE/16 fr. Results The median follow-up period was 62 months (range, 6.8-147.5 months). Seventy percent of patients were followed for 5 years or until death. The 5-year local control, overall survival, and disease-free survival rates were 77.2%, 81.1%, and 50.3%, respectively. Forty-one patients had a local recurrence. Sex, tumor volume, level of proximal invasion, and irradiated dose were unrelated to local control. There was grade 3 toxicity of the peripheral nerves in 6 patients and grade 4 toxicity of the skin in 2 patients. Ambulation remained in 97% of patients. Conclusions Carbon ion radiation therapy was safe and effective for unresectable chordoma and provided good local control and survival while preserving ambulation.
AB - Purpose To evaluate the results of carbon ion radiation therapy administered to 188 patients with unresectable primary sacral chordomas. Patients and Methods One hundred eighty-eight patients were treated with carbon ion radiation therapy at a single institute between 1996 and 2013 and retrospectively analyzed. The median age was 66 years. The highest proximal invasion reached past S2 level in 137 patients. The median clinical target volume was 345 cm3. One hundred six patients received 67.2 gray equivalents (GyE)/16 fractions (fr), 74 patients received 70.4 GyE/16 fr, 7 patients received 73.6 GyE/16 fr, and 1 patient received 64.0 GyE/16 fr. Results The median follow-up period was 62 months (range, 6.8-147.5 months). Seventy percent of patients were followed for 5 years or until death. The 5-year local control, overall survival, and disease-free survival rates were 77.2%, 81.1%, and 50.3%, respectively. Forty-one patients had a local recurrence. Sex, tumor volume, level of proximal invasion, and irradiated dose were unrelated to local control. There was grade 3 toxicity of the peripheral nerves in 6 patients and grade 4 toxicity of the skin in 2 patients. Ambulation remained in 97% of patients. Conclusions Carbon ion radiation therapy was safe and effective for unresectable chordoma and provided good local control and survival while preserving ambulation.
UR - http://www.scopus.com/inward/record.url?scp=84963623571&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84963623571&partnerID=8YFLogxK
U2 - 10.1016/j.ijrobp.2016.02.012
DO - 10.1016/j.ijrobp.2016.02.012
M3 - Article
C2 - 27084649
AN - SCOPUS:84963623571
SN - 0360-3016
VL - 95
SP - 322
EP - 327
JO - International Journal of Radiation Oncology Biology Physics
JF - International Journal of Radiation Oncology Biology Physics
IS - 1
ER -
